Drug Profile
HEP 1732
Alternative Names: HEP-1732Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator TGV-Laboratories
- Class Anti-infectives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis C
- No development reported Liver cirrhosis
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for research development in Hepatitis-C in USA (PO, Capsule)
- 28 Aug 2019 No recent reports of development identified for research development in Liver-Cirrhosis in USA (PO, Capsule)
- 24 Aug 2017 Phase-II development is ongoing in Russia (PO) (TGV-Laboratories Pipeline, August 2017)